Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment

Toshio Kubo, Nagio Takigawa, Katsuyuki Kiura, Ayumi Nishida, Nobuaki Ochi, Hiromi Kashihara, Shigeki Umemura, Akiko Hisamoto, Mitsune Tanimoto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A 51-year-old female presented with left facial palsy. She had adenocarcinoma of the lung with multiple brain metastases. The primary tumor regressed after treatment with gefitinib, however, neurological symptoms progressed rapidly because of meningeal carcinomatosis, when a deletion mutation in exon 19 of the epidermal growth factor receptor in cells from her cerebrospinal fluid was detected. After performing lumbo-peritoneal shunting, her symptoms improved dramatically and she had been well without peritoneal dissemination for 15 months, continuing gefitinib treatment. Finally, she died 18 months after lumbo-peritoneal shunting. A T790M acquired-resistance mutation in exon 20 of the epidermal growth factor receptor was found from her mesenteric lymph nodes and cerebrospinal fluid at autopsy. A lumbo-peritoneal shunt might be considered for meningeal carcinomatosis refractory to gefitinib treatment without an emergence of a T790M mutation.

Original languageEnglish
Pages (from-to)2759-2760
Number of pages2
JournalAnticancer Research
Volume29
Issue number7
Publication statusPublished - Jul 2009

Fingerprint

Meningeal Carcinomatosis
Epidermal Growth Factor Receptor
Cerebrospinal Fluid
Exons
Mutation
Sequence Deletion
Facial Paralysis
Autopsy
Lymph Nodes
Neoplasm Metastasis
Brain
gefitinib
Neoplasms

Keywords

  • Epidermal growth factor receptor
  • Gefitinib
  • Lumbo-peritoneal shunt
  • Lung cancer
  • Meningeal carcinomatosis
  • T790M

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kubo, T., Takigawa, N., Kiura, K., Nishida, A., Ochi, N., Kashihara, H., ... Tanimoto, M. (2009). Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment. Anticancer Research, 29(7), 2759-2760.

Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment. / Kubo, Toshio; Takigawa, Nagio; Kiura, Katsuyuki; Nishida, Ayumi; Ochi, Nobuaki; Kashihara, Hiromi; Umemura, Shigeki; Hisamoto, Akiko; Tanimoto, Mitsune.

In: Anticancer Research, Vol. 29, No. 7, 07.2009, p. 2759-2760.

Research output: Contribution to journalArticle

Kubo, T, Takigawa, N, Kiura, K, Nishida, A, Ochi, N, Kashihara, H, Umemura, S, Hisamoto, A & Tanimoto, M 2009, 'Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment', Anticancer Research, vol. 29, no. 7, pp. 2759-2760.
Kubo, Toshio ; Takigawa, Nagio ; Kiura, Katsuyuki ; Nishida, Ayumi ; Ochi, Nobuaki ; Kashihara, Hiromi ; Umemura, Shigeki ; Hisamoto, Akiko ; Tanimoto, Mitsune. / Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment. In: Anticancer Research. 2009 ; Vol. 29, No. 7. pp. 2759-2760.
@article{b5ed7851f4c2452db41b5ac061a6f102,
title = "Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment",
abstract = "A 51-year-old female presented with left facial palsy. She had adenocarcinoma of the lung with multiple brain metastases. The primary tumor regressed after treatment with gefitinib, however, neurological symptoms progressed rapidly because of meningeal carcinomatosis, when a deletion mutation in exon 19 of the epidermal growth factor receptor in cells from her cerebrospinal fluid was detected. After performing lumbo-peritoneal shunting, her symptoms improved dramatically and she had been well without peritoneal dissemination for 15 months, continuing gefitinib treatment. Finally, she died 18 months after lumbo-peritoneal shunting. A T790M acquired-resistance mutation in exon 20 of the epidermal growth factor receptor was found from her mesenteric lymph nodes and cerebrospinal fluid at autopsy. A lumbo-peritoneal shunt might be considered for meningeal carcinomatosis refractory to gefitinib treatment without an emergence of a T790M mutation.",
keywords = "Epidermal growth factor receptor, Gefitinib, Lumbo-peritoneal shunt, Lung cancer, Meningeal carcinomatosis, T790M",
author = "Toshio Kubo and Nagio Takigawa and Katsuyuki Kiura and Ayumi Nishida and Nobuaki Ochi and Hiromi Kashihara and Shigeki Umemura and Akiko Hisamoto and Mitsune Tanimoto",
year = "2009",
month = "7",
language = "English",
volume = "29",
pages = "2759--2760",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

TY - JOUR

T1 - Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment

AU - Kubo, Toshio

AU - Takigawa, Nagio

AU - Kiura, Katsuyuki

AU - Nishida, Ayumi

AU - Ochi, Nobuaki

AU - Kashihara, Hiromi

AU - Umemura, Shigeki

AU - Hisamoto, Akiko

AU - Tanimoto, Mitsune

PY - 2009/7

Y1 - 2009/7

N2 - A 51-year-old female presented with left facial palsy. She had adenocarcinoma of the lung with multiple brain metastases. The primary tumor regressed after treatment with gefitinib, however, neurological symptoms progressed rapidly because of meningeal carcinomatosis, when a deletion mutation in exon 19 of the epidermal growth factor receptor in cells from her cerebrospinal fluid was detected. After performing lumbo-peritoneal shunting, her symptoms improved dramatically and she had been well without peritoneal dissemination for 15 months, continuing gefitinib treatment. Finally, she died 18 months after lumbo-peritoneal shunting. A T790M acquired-resistance mutation in exon 20 of the epidermal growth factor receptor was found from her mesenteric lymph nodes and cerebrospinal fluid at autopsy. A lumbo-peritoneal shunt might be considered for meningeal carcinomatosis refractory to gefitinib treatment without an emergence of a T790M mutation.

AB - A 51-year-old female presented with left facial palsy. She had adenocarcinoma of the lung with multiple brain metastases. The primary tumor regressed after treatment with gefitinib, however, neurological symptoms progressed rapidly because of meningeal carcinomatosis, when a deletion mutation in exon 19 of the epidermal growth factor receptor in cells from her cerebrospinal fluid was detected. After performing lumbo-peritoneal shunting, her symptoms improved dramatically and she had been well without peritoneal dissemination for 15 months, continuing gefitinib treatment. Finally, she died 18 months after lumbo-peritoneal shunting. A T790M acquired-resistance mutation in exon 20 of the epidermal growth factor receptor was found from her mesenteric lymph nodes and cerebrospinal fluid at autopsy. A lumbo-peritoneal shunt might be considered for meningeal carcinomatosis refractory to gefitinib treatment without an emergence of a T790M mutation.

KW - Epidermal growth factor receptor

KW - Gefitinib

KW - Lumbo-peritoneal shunt

KW - Lung cancer

KW - Meningeal carcinomatosis

KW - T790M

UR - http://www.scopus.com/inward/record.url?scp=69249167989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249167989&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 2759

EP - 2760

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -